Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II atezolizumab consolidation in high-risk diffuse large B-cell lymphoma
2017-002605-35Phase 2Active
- Sponsor
- HOVON
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by HOVON. Primary endpoint: Disease-free survival. Started Mar 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2017-002605-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002605-35.